Incyte and Moffitt team up for blood cancer research programmes
Posted: 1 June 2016 | Victoria White, Digital Content Producer | No comments yet
Incyte has agreed to provide funding to conduct three new Moffitt Cancer Centre research programmes over a period of three years…
Incyte and Moffitt Cancer Centre have entered into a research support and collaboration agreement, whereby Incyte has agreed to provide funding to conduct three new Moffitt Cancer Centre research programmes over a period of three years.
The research programmes will be focused on specific blood cancers, including myeloproliferative neoplasms (MPNs), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL) and chronic myelomonocytic leukaemia (CMML). The objective of this alliance is to develop an improved understanding of basic cancer biology in the areas of focus, and interrogate specific therapeutic hypotheses involving Incyte’s proprietary small molecule therapeutics, both as single agents and in combination.
Incyte to provide financial support for the research programmes
Commenting on the new collaboration, Jarett Rieger, Senior Director of Moffitt’s Office of Innovation and Industry Alliances and Associate General Counsel, said: “Having access to Incyte’s diverse pipeline of targeted cancer therapies represents a unique and exciting opportunity for Moffitt researchers to expand our efforts to advance medical research in oncology and improve medical care for patients with cancer. A huge strength of Moffitt is our ability to form inter-disciplinary research teams, and this exciting research alliance, involving numerous faculty members, is a testament to our team science culture.”
Incyte will provide financial support for three research programmes over the three year period of the collaboration.
“Incyte and Moffitt are both committed to improving the lives of patients with cancer through the discovery and development of novel medicines. This research alliance will enable new and important research into multiple blood cancers in a manner that both leverages and extends our current drug discovery efforts,” stated Reid Huber, Ph.D., Incyte’s Chief Scientific Officer. “We are pleased to expand our growing network of academic collaborations and join forces with the world class investigators from Moffitt to advance the landscape of cancer treatment.”